scholarly journals RADIONUCLIDE METHODS FOR DIAGNOSIS AND TREATMENT ASSESSMENT OF BREAST CANCER

2019 ◽  
Vol 33 (4) ◽  
pp. 44-53
Author(s):  
R. Yu. Vernadsky ◽  
A. A. Medvedeva ◽  
E. Yu. Garbukov ◽  
V. I. Chernov ◽  
E. M. Slonimskaia
Keyword(s):  
Breast Cancer ◽  
Molecular Imaging ◽  
Breast Imaging ◽  
Potential Role ◽  
Response To Therapy ◽  
Diagnostic Methods ◽  
Whole Body ◽  
Chemotherapy Response ◽  
Whole Body Imaging ◽  
Biological Processes

Molecular imaging is a multimodal discipline for visualizing biological processes at the subcellular level in vivo. These diagnostic methods could be potentially used for screening and staging of cancer as well as for monitoring of treatment. Formerly, mostly anatomical information played key role in medical visualization. Now, molecular visualization allows improving diagnostic parameters of standard diagnostic methods. Molecular imaging allows not only for localization of tumor, but also for visualization of biological processes that influence tumor behavior and response to therapy. This review reflects the potential role of radionuclide methods and radiopharmaceuticals in diagnostic and assessment of tumor response. The paper covers indications and capabilities of dedicated nuclear breast imaging systems such as breast-specific g-imaging and positron-emission mammography. The accuracy of different methods was analyzed. The analysis showed that new technological solutions allow to significantly increase informativeness of examinations through improved spatial resolution compared to whole-body imaging cameras. Molecular imaging is useful for neoadjuvant chemotherapy response monitoring and is highly sensitive for prediction of non-responsiveness during treatment of breast cancer. The sensitivity of molecular breast imaging is comparable with that of magnetic resonance imaging, but has higher specificity. Molecular imaging may play a great potential role in the diagnostic algorithm for breast cancer.

scholarly journals Radionuclide-Based Imaging of Breast Cancer: State of the Art

Cancers ◽  
2021 ◽  
Vol 13 (21) ◽  
pp. 5459
Author(s):  
Huiling Li ◽  
Zhen Liu ◽  
Lujie Yuan ◽  
Kevin Fan ◽  
Yongxue Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Imaging ◽  
Single Photon ◽  
Morphological Changes ◽  
Imaging Techniques ◽  
Rapid Development ◽  
Photon Emission ◽  
Emission Computed Tomography ◽  
Biological Processes ◽  
Functional Perspective

Breast cancer is a malignant tumor that can affect women worldwide and endanger their health and wellbeing. Early detection of breast cancer can significantly improve the prognosis and survival rate of patients, but with traditional anatomical imagine methods, it is difficult to detect lesions before morphological changes occur. Radionuclide-based molecular imaging based on positron emission tomography (PET) and single-photon emission computed tomography (SPECT) displays its advantages for detecting breast cancer from a functional perspective. Radionuclide labeling of small metabolic compounds can be used for imaging biological processes, while radionuclide labeling of ligands/antibodies can be used for imaging receptors. Noninvasive visualization of biological processes helps elucidate the metabolic state of breast cancer, while receptor-targeted radionuclide molecular imaging is sensitive and specific for visualization of the overexpressed molecular markers in breast cancer, contributing to early diagnosis and better management of cancer patients. The rapid development of radionuclide probes aids the diagnosis of breast cancer in various aspects. These probes target metabolism, amino acid transporters, cell proliferation, hypoxia, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), gastrin-releasing peptide receptor (GRPR) and so on. This article provides an overview of the development of radionuclide molecular imaging techniques present in preclinical or clinical studies, which are used as tools for early breast cancer diagnosis.

Predictors of advanced imaging use during breast cancer surveillance.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18337-e18337
Author(s):  
Randy C. Miles ◽  
Christoph I. Lee ◽  
Qin Sun ◽  
Aasthaa Bansal ◽  
Catherine R. Fedorenko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
Claims Data ◽  
Breast Mri ◽  
Cancer Surveillance ◽  
Whole Body ◽  
Tumor Biomarker ◽  
Whole Body Imaging ◽  
Advanced Imaging ◽  
Body Imaging

e18337 Background: Our objectives were to determine advanced imaging use (whole body imaging with bone scan, CT, or PET-CT and breast MRI) during breast cancer surveillance, and to identify drivers of potential imaging overuse as outlined by ASCO’s Choosing Wisely initiative. Methods: Cancer registry records for 2923 women diagnosed with primary breast cancer in Washington State from January 1, 2007 to December 31, 2014 were linked with claims data from two regional commercial insurance plans. Inclusion criteria included women with AJCC stage 0-3 disease treated with curative intent. Women without continuous insurance enrollment from 3 months prior to diagnosis until 14 months after diagnosis were excluded. Surveillance began 4 months after the end of primary therapy and lasted for 15 months or until restart of treatment. Women’s (age, race, family history) and tumor (grade, receptor status, stage) characteristics were collected. Evaluation and management codes from claims data were used to determine mammography, advanced imaging, and tumor biomarker use during the peri-diagnostic and surveillance periods. Multivariate logistic regression models were used to identify factors associated with advanced imaging use during surveillance. Results: Of eligible women, 80.0% (2332/2923) received mammography, 16.5% (483/2932) received whole body imaging, and 21.5% (670/2932) received breast MRI during the surveillance period. Whole body imaging was significantly associated with increasing stage of disease (stage 3: OR = 3.39, 95% CI: 2.30-5.02), peri-diagnostic whole body imaging (OR = 1.80, 95% CI: 1.36-2.38), and surveillance tumor biomarker use (OR = 1.83, 95% CI: 1.46-2.31). Significant predictors of surveillance breast MRI included young age ( < 45 years: OR = 2.40, 95% CI:1.78- 3.25), family history (OR = 1.58, 95% CI:1.26-1.98), peri-diagnostic breast MRI (OR = 2.01, 95% CI: 1.56-2.59), and surveillance tumor biomarker use (OR = 1.74, 95% CI:1.41-2.17). Conclusions: Peri-diagnostic use of advanced imaging and surveillance use of tumor biomarkers are associated with advanced imaging use during surveillance, and may represent targets for interventions to increase adherence to Choosing Wisely clinical guidelines.

scholarly journals Comparison between whole-body MRI and Fluorine-18-Fluorodeoxyglucose PET or PET/CT in oncology: a systematic review

2013 ◽  
Vol 47 (3) ◽  
pp. 206-218 ◽  
Author(s):  
Mario Ciliberto ◽  
Fabio Maggi ◽  
Giorgio Treglia ◽  
Federico Padovano ◽  
Lucio Calandriello ◽  
...  
Keyword(s):  
Systematic Review ◽  
Fdg Pet ◽  
Imaging Techniques ◽  
Diagnostic Methods ◽  
Whole Body ◽  
Published Data ◽  
Whole Body Imaging ◽  
Positron Emission ◽  
Pet Ct ◽  
Fluorine 18 Fluorodeoxyglucose

Abstract Background. The aim of the article is to systematically review published data about the comparison between positron emission tomography (PET) or PET/computed tomography (PET/CT) using Fluorine-18-Fluorodeoxyglucose (FDG) and whole-body magnetic resonance imaging (WB-MRI) in patients with different tumours. Methods. A comprehensive literature search of studies published in PubMed/MEDLINE, Scopus and Embase databases through April 2012 and regarding the comparison between FDG-PET or PET/CT and WB-MRI in patients with various tumours was carried out. Results. Forty-four articles comprising 2287 patients were retrieved in full-text version, included and discussed in this systematic review. Several articles evaluated mixed tumours with both diagnostic methods. Concerning the specific tumour types, more evidence exists for lymphomas, bone tumours, head and neck tumours and lung tumours, whereas there is less evidence for other tumour types. Conclusions. Overall, based on the literature findings, WB-MRI seems to be a valid alternative method compared to PET/CT in oncology. Further larger prospective studies and in particular cost-effectiveness analysis comparing these two whole-body imaging techniques are needed to better assess the role of WB-MRI compared to FDG-PET or PET/ CT in specific tumour types.

scholarly journals Optical Imaging in Breast Cancer Diagnosis: The Next Evolution

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Michel Herranz ◽  
Alvaro Ruibal
Keyword(s):  
Breast Cancer ◽  
Optical Imaging ◽  
Breast Imaging ◽  
Near Infrared ◽  
High Sensitivity ◽  
Breast Cancer Diagnosis ◽  
Diagnostic Methods ◽  
Infrared Light ◽  
Western World ◽  
Positron Emission

Breast cancer is one of the most common cancers among the population of the Western world. Diagnostic methods include mammography, ultrasound, and magnetic resonance; meanwhile, nuclear medicine techniques have a secondary role, being useful in regional assessment and therapy followup. Optical imaging is a very promising imaging technique that uses near-infrared light to assess optical properties of tissues and is expected to play an important role in breast cancer detection. Optical breast imaging can be performed by intrinsic breast tissue contrast alone (hemoglobin, water, and lipid content) or with the use of exogenous fluorescent probes that target specific molecules for breast cancer. Major advantages of optical imaging are that it does not use any radioactive components, very high sensitivity, relatively inexpensive, easily accessible, and the potential to be combined in a multimodal approach with other technologies such as mammography, ultrasound, MRI, and positron emission tomography. Moreover, optical imaging agents could, potentially, be used as “theranostics,” combining the process of diagnosis and therapy.

scholarly journals Accuracy and diagnostic value of diffusion-weighted whole body imaging with background body signal suppression (DWIBS) in metastatic breast cancer

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Mohamed Gaber Eissawy ◽  
Amr M. Ismaeel Saadawy ◽  
Kamel Farag ◽  
Tamer Akl ◽  
Wael Hamza Kamr
Keyword(s):  
Breast Cancer ◽  
Soft Tissue ◽  
Metastatic Breast ◽  
Whole Body ◽  
Whole Body Imaging ◽  
Solid Organ ◽  
Body Imaging ◽  
Predictive Values ◽  
Diffusion Weighted ◽  
Signal Suppression

Abstract Background Breast cancer is the most common malignant tumor among women. The mortality of the patients could be mainly attributed to metastasis and spread of breast cancer to distant sites. The objective of the current study is to evaluate and express the role of diffusion-weighted whole body imaging with background body signal suppression (DWIBS) in detection of osseous and soft tissue metastatic lesions in patients with cancer breast. Results The current prospective study included 50 female patients with pathologically proven breast cancer. The overall sensitivity of DWIBS and STIR were 97.5% and 92.5%, respectively. DWIBS was the most sensitive sequence with highest negative predictive values. DWIBS and STIR were the most sensitive with the highest negative predictive value. Both DWIBS and STIR detected more vertebral metastatic deposits (100% and 97.8%, respectively) and more soft tissue lesions (94.4% for both) than WB DWI and T1WI. Conclusion DWIBS MRI sequence is an effective method for detection of solid organ, bone and lymph node metastasis but not specific for characterization of lesions.

Sign in / Sign up

Export Citation Format

Share Document